Company intelligence / Profile preview

FivepHusion

Austinmer, NSW, Australia

Ownership: Private
Development stage: Other

Overview

FivepHusion's lead asset Deflexifol is a proprietary, novel co-formulation combining 5-fluorouracil (5-FU) and leucovorin (LV), with anticipated peak revenues exceeding US$1 billion. The company is also developing Deflexifol for pediatric ependymoma, a rare and deadly brain cancer affecting young children.

Therapeutic areas: Oncology
Modalities: Small moleculeDevice/Technology platform
Industry: Investors

Partnerships

Allarity Therapeutics Inc (collaboration on Deflexifol development)University of Wollongong (ResectAssist technology development)

Beyond the preview

Go deeper on FivepHusion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FivepHusion.

Explore the full profile